(CATX) Perspective Therapeutics - Ratings and Ratios
Cancer, Imaging, Isotopes, Target, Therapy
CATX EPS (Earnings per Share)
CATX Revenue
Description: CATX Perspective Therapeutics
Perspective Therapeutics Inc. (NYSE MKT:CATX) is a biopharmaceutical company focused on developing precision targeted alpha therapies (TAT) to treat cancer. The companys pipeline includes several promising candidates, including VMT-a-NET, VMT01, PSV359, and PSV4XX, targeting various types of cancer such as neuroendocrine tumors, melanoma, and prostate cancer.
From a clinical perspective, VMT-a-NET and VMT01 are in Phase 1/2a clinical trials, indicating a potentially significant near-term catalyst for the stock. The companys collaboration with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with melanoma further validates its technology and potentially expands its therapeutic applications.
To evaluate the companys performance, key performance indicators (KPIs) such as cash runway, burn rate, and clinical trial progress are crucial. With a market capitalization of $279.10M USD, investors should monitor the companys cash position and burn rate to assess its ability to fund ongoing and future clinical trials. Additionally, metrics such as the number of patients enrolled in ongoing trials, trial completion rates, and objective response rates (ORR) will be essential in determining the potential success of its pipeline candidates.
From a valuation perspective, the absence of a price-to-earnings (P/E) ratio is not surprising given the companys negative return on equity (RoE) of -27.37%. Investors should focus on other metrics such as enterprise value-to-cash flow or price-to-book ratios, as well as industry comparables, to gauge the stocks relative valuation. The companys progress in clinical trials and potential future revenue streams will be critical in driving its valuation.
CATX Stock Overview
| Market Cap in USD | 263m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2005-11-10 |
CATX Stock Ratings
| Growth Rating | -27.2% |
| Fundamental | 15.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -79.0% |
| Analyst Rating | 4.64 of 5 |
CATX Dividends
Currently no dividends paidCATX Growth Ratios
| Growth Correlation 3m | -41.7% |
| Growth Correlation 12m | -38.2% |
| Growth Correlation 5y | -19.3% |
| CAGR 5y | -1.30% |
| CAGR/Max DD 3y | -0.01 |
| CAGR/Mean DD 3y | -0.04 |
| Sharpe Ratio 12m | -0.68 |
| Alpha | 0.14 |
| Beta | 0.451 |
| Volatility | 90.59% |
| Current Volume | 1016.5k |
| Average Volume 20d | 563.1k |
| Stop Loss | 3 (-8.3%) |
| Signal | -2.31 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-113.6m TTM) > 0 and > 6% of Revenue (6% = 34.6k TTM) |
| FCFTA -0.23 (>2.0%) and ΔFCFTA -13.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.8k% (prev 12.6k%; Δ 19.1kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.19 (>3.0%) and CFO -58.7m > Net Income -113.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 15.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (70.7m) change vs 12m ago 6.04% (target <= -2.0% for YES) |
| Gross Margin -150.2% (prev 35.57%; Δ -185.7pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.17% (prev 0.58%; Δ -0.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -308.5 (EBITDA TTM -117.2m / Interest Expense TTM 389.0k) >= 6 (WARN >= 3) |
Altman Z'' -7.63
| (A) 0.59 = (Total Current Assets 196.0m - Total Current Liabilities 13.0m) / Total Assets 310.7m |
| (B) -0.87 = Retained Earnings (Balance) -271.4m / Total Assets 310.7m |
| (C) -0.34 = EBIT TTM -120.0m / Avg Total Assets 348.3m |
| (D) -6.02 = Book Value of Equity -271.3m / Total Liabilities 45.0m |
| Total Rating: -7.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 14.97
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -98.58% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.02 = -2.50 |
| 6. ROIC - WACC (= -48.45)% = -12.50 |
| 7. RoE -38.87% = -2.50 |
| 8. Rev. Trend -82.29% = -6.17 |
| 9. EPS Trend -77.08% = -3.85 |
What is the price of CATX shares?
Over the past week, the price has changed by -2.97%, over one month by -11.38%, over three months by -9.42% and over the past year by -75.08%.
Is Perspective Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CATX is around 2.78 USD . This means that CATX is currently overvalued and has a potential downside of -14.98%.
Is CATX a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CATX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14 | 326.9% |
| Analysts Target Price | 14 | 326.9% |
| ValueRay Target Price | 3.1 | -5.8% |
Last update: 2025-09-06 04:34
CATX Fundamental Data Overview
CCE Cash And Equivalents = 191.6m USD (Cash And Short Term Investments, last quarter)
P/S = 212.8672
P/B = 0.9895
Beta = 1.211
Revenue TTM = 576.0k USD
EBIT TTM = -120.0m USD
EBITDA TTM = -117.2m USD
Long Term Debt = 1.60m USD (from longTermDebt, last quarter)
Short Term Debt = 847.0k USD (from shortTermDebt, last quarter)
Debt = 2.44m USD (Calculated: Short Term 847.0k + Long Term 1.60m)
Net Debt = -26.9m USD (from netDebt column, last quarter)
Enterprise Value = 73.8m USD (262.9m + Debt 2.44m - CCE 191.6m)
Interest Coverage Ratio = -308.5 (Ebit TTM -120.0m / Interest Expense TTM 389.0k)
FCF Yield = -98.58% (FCF TTM -72.7m / Enterprise Value 73.8m)
FCF Margin = -12.6k% (FCF TTM -72.7m / Revenue TTM 576.0k)
Net Margin = -19.7k% (Net Income TTM -113.6m / Revenue TTM 576.0k)
Gross Margin = -150.2% ((Revenue TTM 576.0k - Cost of Revenue TTM 1.44m) / Revenue TTM)
Tobins Q-Ratio = -0.27 (set to none) (Enterprise Value 73.8m / Book Value Of Equity -271.3m)
Interest Expense / Debt = 4.87% (Interest Expense 119.0k / Debt 2.44m)
Taxrate = 21.0% (US default)
NOPAT = -120.0m (EBIT -120.0m, no tax applied on loss)
Current Ratio = 15.09 (Total Current Assets 196.0m / Total Current Liabilities 13.0m)
Debt / Equity = 0.01 (Debt 2.44m / last Quarter total Stockholder Equity 265.7m)
Debt / EBITDA = -0.02 (Net Debt -26.9m / EBITDA -117.2m)
Debt / FCF = -0.03 (Debt 2.44m / FCF TTM -72.7m)
Total Stockholder Equity = 292.4m (last 4 quarters mean)
RoA = -36.57% (Net Income -113.6m, Total Assets 310.7m )
RoE = -38.87% (Net Income TTM -113.6m / Total Stockholder Equity 292.4m)
RoCE = -40.82% (Ebit -120.0m / (Equity 292.4m + L.T.Debt 1.60m))
RoIC = -40.81% (NOPAT -120.0m / Invested Capital 294.0m)
WACC = 7.64% (E(262.9m)/V(265.3m) * Re(7.68%)) + (D(2.44m)/V(265.3m) * Rd(4.87%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 62.67 | Cagr: 2.32%
Discount Rate = 7.68% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -72.7m)
EPS Correlation: -77.08 | EPS CAGR: -20.93% | SUE: 0.0 | # QB: 0
Revenue Correlation: -82.29 | Revenue CAGR: -51.55%
Additional Sources for CATX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle